Unity Biotechnology UBX1325 (foselutoclax) senolytic

A dated reading of what is claimed, reported, and independently verified in the current evidence.

Current reading

The readiness gap, in one scan

AI-assisted assembly · derived results

Evidence strength Weak

Decision

Human editorial judgment · 2026-06-28

Do not rely on; treat as orphaned asset

Why: The lead senolytic clinical asset missed its primary endpoint and its sponsor has been formally dissolved (delisted, liquidation approved, certificate of dissolution effective Sept 2025). The mechanism and safety profile remain mechanistically promising, but with no corporate vehicle and no named acquirer/financing, near-term reliance is unwarranted.
Next: Monitor for any acquirer that buys UBX1325 out of Unity's dissolution estate and names a financed Phase 3 plan; until then do not treat foselutoclax as a viable independent senolytic asset — the sponsor no longer exists

Constraints

No named blocker is present in the current public projection.

Evidence summary

AI-assisted assembly

Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.

Publication record

Initial public reading

This is the initial public reading. No earlier readiness change is recorded.